Athletes are preparing to compete openly using performance-enhancing substances for the first time at the Enhanced Games in Las Vegas. Organizers present the event as a new direction for elite sport, but the established sporting world has condemned it as dangerous and irresponsible.

The competition, founded by Australian businessman Aron D’Souza, relaxes conventional anti-doping rules. Compounds must be approved by the US Food and Drug Administration and taken under medical supervision, but otherwise athletes are free to choose their protocols. That approach has prompted fierce debate about safety, fairness and exploitation.

Enhancement in sport is not a recent invention. Bioethicist Andy Miah notes that ancient athletes used various means to try to gain an edge — from olive oil to alcohol — and modern sport has a long history of pharmacological aids. Contemporary enhancement strategies are better understood scientifically, and many fall into a few broad categories: anabolic steroids that build muscle and speed recovery; blood-doping and erythropoietin (EPO) that increase oxygen delivery; stimulants that combat fatigue; and peptides or hormone modulators that can raise levels of testosterone or other regulators.

Physiologist Michael Joyner observes that steroids, blood-doping/EPO and amphetamines have clear performance effects, while the evidence is more mixed for many newer peptides and experimental compounds.

Much of the biology behind these approaches has been around for a long time, says Arthur Caplan, who leads medical ethics at NYU Grossman School of Medicine. Growth hormones, stimulants used for attention, and pain medicines that blunt warning signals are familiar tools that athletes and trainers have adapted for competitive advantage.

Those substances bring two kinds of risk. Primary risks are direct medical harms: for example, growth hormones may raise cancer risk, and anabolic steroids have long been linked to cardiovascular disease. Secondary risks arise when one system in the body is driven beyond what the rest can support. Building large amounts of muscle without strengthening tendons, joints and connective tissue can lead to catastrophic structural failures — severe strains, ruptured tendons, spinal damage and other injuries that may be disabling.

Organizers of the Enhanced Games emphasize medical oversight, but critics argue safety is being deprioritized in favor of spectacle. Caplan warns that some backers, including prominent tech investors, seem motivated by the thrill of extreme performance and may not prioritize athletes’ long-term wellbeing. The event has drawn high-profile supporters and attracted attention for its willingness to push boundaries.

Bioethicists also point to the social and economic contexts that influence athletes’ choices. Many participants may be driven by vulnerability: the end of a career, financial pressures, or the realization that they cannot reach the top in conventional competition. That dynamic raises questions about true voluntariness and whether consent under these conditions genuinely protects athletes.

Looking beyond the substances currently in use, researchers and some athletes are turning to more experimental biological interventions. Strategies include inhibiting myostatin, a protein that limits muscle growth; animals without myostatin are markedly more muscular, suggesting the pathway could create large strength gains if blocked in humans. Even more radical are gene-editing techniques such as CRISPR, which could theoretically modify genes related to endurance, metabolism or muscle development. Unlike temporary pharmacology, genetic alterations could produce long-term changes and, potentially, be heritable.

Those possibilities raise profound ethical and safety concerns. Intervening at the molecular or genetic level is fundamentally different from taking a drug for a season. The long-term consequences are uncertain, and the idea of experimenting on healthy individuals purely to test performance-enhancing interventions is ethically fraught. Miah notes that conducting the kinds of controlled studies needed to establish safety would be difficult to justify in healthy people without a medical indication.

Whether regulated, medicalized enhancement could ever become safe and ethically acceptable remains an open question. Proponents argue for bodily autonomy and innovation; critics worry about coercion, unequal access, long-term health harms and a potential arms race of biological modification. For now, the Enhanced Games represent a provocative experiment in which the potential for spectacular performances is matched by serious and sometimes irreversible medical and ethical risks.

Edited by: Zulfikar Abbany

The inaugural Enhanced Games in Las Vegas has thrust a radical experiment into the public eye: elite athletes competing without traditional anti-doping rules, able to use FDA‑approved performance aids under medical supervision. Promoted by Australian entrepreneur Aron D’Souza as a new frontier for sport, the event has been blasted by the established sporting world — including WADA — as dangerous and irresponsible.

The idea of using substances or techniques to gain an edge is not new. Ancient athletes oiled their bodies and early modern competitors sometimes drank alcohol before contests, believing it helped. Today’s enhancement toolbox is far more powerful and better understood. Experts group common strategies into three main categories: anabolic agents that build muscle and speed recovery; blood‑boosting approaches such as EPO or transfusions that raise oxygen delivery; and stimulants that blunt fatigue. A range of peptides and hormonal modulators can also nudge the body to produce more testosterone, EPO and other effectors.

Physiologists acknowledge clear evidence that steroids, blood doping and stimulants work. But effectiveness comes with significant health costs. Some drugs carry direct, long‑term risks: growth hormone has been linked to higher cancer risk, and anabolic steroids are associated with cardiovascular disease. Beyond these primary dangers, clinicians warn of secondary harms that arise when enhancement alters one part of the body without strengthening complementary systems. Rapidly enlarged muscles, for example, can overload tendons, ligaments and joints — raising the chance of severe, even career‑ending injuries.

Critics also say the Enhanced Games sideline safety in pursuit of spectacle. Bioethicists point to a troubling dynamic: many participating athletes are not elite stars choosing enhancement from a position of strength but competitors facing financial pressure, injury, or the twilight of a career. That raises questions about consent and exploitation. Observers compare some backers’ appetite for extreme performance to a modern form of gladiatorial entertainment, driven by investors who prioritize thrilling displays over athlete welfare.

Higher‑tech interventions loom behind the drugs already in use. Researchers are exploring ways to block myostatin, a protein that limits muscle growth; animals lacking myostatin are dramatically more muscular, and the same effect in humans could yield big performance gains. Even more consequential is the advance of gene editing tools such as CRISPR. Unlike temporary pharmacological tweaks, changes to genes linked to endurance, metabolism or muscle growth would alter an athlete’s biology more permanently — and could be heritable if germline edits are made.

Those possibilities amplify ethical and safety concerns. Gene and molecular interventions operate on a different scale than conventional doping, carrying unknown long‑term effects and the potential to affect future generations. Some ethicists fear we are on the brink of interventions that cannot be tested ethically on healthy people, because deliberate experimentation with invasive biological changes in otherwise healthy subjects is difficult to justify.

Organizers of the Enhanced Games argue the event celebrates bodily autonomy and a new approach to performance. But critics counter that autonomy is complicated when choices are made under economic or career duress and when the risks are both poorly understood and potentially catastrophic. The mix of financial backers and high‑stakes curiosity only heightens worries that athlete welfare may be subordinated to entertainment value and the investors’ desire to see extraordinary outcomes.

In short, while the spectacle highlights advances in performance science, the deeper problem is not limited to acute injuries. The combination of established but harmful pharmacology, risky secondary injuries caused by imbalanced physiological changes, and the looming prospect of genetic alteration raises thorny medical, ethical and social questions. Whether enhanced sport can ever be made acceptably safe and ethically sound remains doubtful to many experts, especially given the reluctance to carry out rigorous trials on healthy individuals and the commercial incentives that push toward faster adoption rather than careful study.